IRIDEX Beheer

Beheer criteriumcontroles 3/4

De CEO IRIDEX is Patrick Mercer, benoemd in May2024, heeft een ambtstermijn van minder dan een jaar. De totale jaarlijkse vergoeding van { bedraagt $ 518.07K, bestaande uit 64.9% salaris en 35.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.37% van de aandelen van het bedrijf, ter waarde $ 108.65K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 0.5 jaar en 5.6 jaar.

Belangrijke informatie

Patrick Mercer

Algemeen directeur

US$518.1k

Totale compensatie

Percentage CEO-salaris	64.9%
Dienstverband CEO	less than a year
Eigendom CEO	0.4%
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	5.6yrs

Recente managementupdates

Recent updates

Revenues Working Against IRIDEX Corporation's (NASDAQ:IRIX) Share Price Following 26% Dive

Jun 11

Lacklustre Performance Is Driving IRIDEX Corporation's (NASDAQ:IRIX) 32% Price Drop

Aug 12

Will IRIDEX (NASDAQ:IRIX) Spend Its Cash Wisely?

Apr 14

We're Hopeful That IRIDEX (NASDAQ:IRIX) Will Use Its Cash Wisely

Oct 12

Is IRIDEX (NASDAQ:IRIX) Using Too Much Debt?

Feb 25

Iridex To Benefit From New Revolutionary Glaucoma Treatment

Jan 11

Analysts Expect Breakeven For IRIDEX Corporation (NASDAQ:IRIX) Before Long

Jan 03

IRIDEX says laser therapy now accepted in the European Glaucoma Society guidelines

Dec 23

Analyse CEO-vergoeding

Hoe is Patrick Mercer's beloning veranderd ten opzichte van IRIDEX's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 28 2024	n/a	n/a	-US$11m
Jun 29 2024	n/a	n/a	-US$11m
Mar 30 2024	n/a	n/a	-US$11m
Dec 30 2023	US$518k	US$336k	-US$10m
Sep 30 2023	n/a	n/a	-US$8m
Jul 01 2023	n/a	n/a	-US$8m
Apr 01 2023	n/a	n/a	-US$7m
Dec 31 2022	US$568k	US$317k	-US$8m
Oct 01 2022	n/a	n/a	-US$9m
Jul 02 2022	n/a	n/a	-US$9m
Apr 02 2022	n/a	n/a	-US$6m
Jan 01 2022	US$765k	US$317k	-US$5m
Oct 02 2021	n/a	n/a	-US$3m
Jul 03 2021	n/a	n/a	-US$3m
Apr 03 2021	n/a	n/a	-US$7m
Jan 02 2021	US$472k	US$316k	-US$6m
Sep 26 2020	n/a	n/a	-US$8m
Jun 27 2020	n/a	n/a	-US$8m
Mar 28 2020	n/a	n/a	-US$7m
Dec 28 2019	US$500k	US$277k	-US$9m

Compensatie versus markt: De totale vergoeding ($USD 518.07K ) Patrick } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 646.00K ).

Compensatie versus inkomsten: De vergoeding van Patrick is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Patrick Mercer (52 yo)

less than a year

Tenure

US$518,073

Compensatie

Mr. Patrick Mercer is Chief Executive Officer of IRIDEX Corporation from October 1, 2024 and serves as it's President since May 22, 2024 and was its Chief Operating Officer since September 2018 until Octob...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Scott Shuda	Executive Chairman	5.6yrs	US$154.00k	0.41% $ 121.8k
Patrick Mercer	CEO & President	less than a year	US$518.07k	0.37% $ 108.7k
Fuad Ahmad	Interim Chief Financial Officer	4yrs	US$356.84k	geen gegevens
Leigh Salvo	Head of Investor Relations	no data	geen gegevens	geen gegevens

0.5yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van IRIX wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.5 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Scott Shuda	Executive Chairman	5.6yrs	US$154.00k	0.41% $ 121.8k
Beverly Huss	Independent Director	2.7yrs	US$127.50k	0.17% $ 48.6k
Kenneth Ludlum	Independent Director	5.6yrs	US$134.50k	0.38% $ 110.5k
Robert Grove	Independent Director	6.1yrs	US$119.00k	0.73% $ 213.9k

5.6yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van IRIX wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.6 jaar).

IRIDEX Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

IRIDEX Corporation Announces Board and Committee Changes

Iridex Corporation Announces Chief Executive Officer Changes

IRIDEX Corporation Announces Composition of Audit Committee

IRIDEX Corporation Appoints Patrick Mercer as Its President

IRIDEX Corporation, Annual General Meeting, Jun 18, 2024

Iridex Corporation Modifies the Composition of its Audit Committee, Compensation Committee, and Nominating and Governance Committee

Recent updates

Iridex Corporation Comments on Changing Glaucoma Reimbursement Landscape

IRIDEX Corporation Announces Board and Committee Changes

IRIDEX Corporation to Report Q3, 2024 Results on Nov 12, 2024

Iridex Corporation Announces Chief Executive Officer Changes

IRIDEX Corporation announced that it expects to receive $5 million in funding from The Lind Partners, LLC

IRIDEX Corporation announced that it expects to receive $5 million in funding from The Lind Partners, LLC

IRIDEX Corporation to Report Q2, 2024 Results on Aug 08, 2024

IRIDEX Begins the Process to Transfer the Listing of its Common Stock from The Nasdaq Global Market to The Nasdaq Capital Market

IRIDEX Begins the Process to Transfer the Listing of its Common Stock from The Nasdaq Global Market to The Nasdaq Capital Market

IRIDEX Corporation Announces Composition of Audit Committee

Revenues Working Against IRIDEX Corporation's (NASDAQ:IRIX) Share Price Following 26% Dive

IRIDEX Corporation Appoints Patrick Mercer as Its President

Consensus EPS estimates fall by 32%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Is IRIDEX (NASDAQ:IRIX) In A Good Position To Invest In Growth?

IRIDEX Corporation to Report Q1, 2024 Results on May 14, 2024

IRIDEX Corporation, Annual General Meeting, Jun 18, 2024

Iridex's Strategic Review Process Should Bear Fruit 'Soon'

Full year 2023 earnings: EPS and revenues miss analyst expectations

IRIDEX Corporation to Report Q4, 2023 Results on Mar 26, 2024

Little Excitement Around IRIDEX Corporation's (NASDAQ:IRIX) Revenues

Price target decreased by 48% to US$2.00

Iridex Corporation Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust

Iridex Corporation Launches New Iridex 532 and Iridex 577 Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma

Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation

Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation

IRIDEX Corporation announced delayed 10-Q filing

IRIDEX Corporation announced delayed 10-Q filing

New major risk - Share price stability

IRIDEX Corporation to Report Q3, 2023 Results on Nov 14, 2023

Will IRIDEX (NASDAQ:IRIX) Spend Its Cash Wisely?

Consensus EPS estimates fall by 35%

New minor risk - Share price stability

Lacklustre Performance Is Driving IRIDEX Corporation's (NASDAQ:IRIX) 32% Price Drop

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

IRIDEX Corporation Provides Revenue Guidance for the Year 2023

IRIDEX Corporation to Report Q2, 2023 Results on Aug 10, 2023

First quarter 2023 earnings: EPS misses analyst expectations

IRIDEX Corporation Reiterates Financial Guidance for 2023

Will IRIDEX (NASDAQ:IRIX) Spend Its Cash Wisely?

Consensus EPS estimates fall by 13%

Full year 2022 earnings: EPS exceeds analyst expectations

IRIDEX Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Price target decreased to US$5.63

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

IRIDEX Corporation Provides Revenue Guidance for the Year 2022

IRIDEX Corporation to Report Q3, 2022 Results on Nov 10, 2022

We're Hopeful That IRIDEX (NASDAQ:IRIX) Will Use Its Cash Wisely

Iridex Corporation Showcases its Non-Incisional Treatments for Glaucoma and Introduces Sweep Management Software at AAO 2022

IRIDEX Corporation Revises Revenue Guidance for the Full Year 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

IRIDEX Corporation to Report Q2, 2022 Results on Aug 15, 2022

IRIDEX Corporation Obtains Regulatory Clearance for Cyclo G6(R) Glaucoma Platform in China

IRIDEX Corporation Provides Revenue Guidance for the Full Year 2022

First quarter 2022 earnings: EPS exceeds analyst expectations

Price target increased to US$9.75

Iridex Corporation Modifies the Composition of its Audit Committee, Compensation Committee, and Nominating and Governance Committee

Consensus EPS estimates fall by 62%

Full year 2021 earnings: EPS and revenues exceed analyst expectations

IRIDEX Corporation to Report Q4, 2021 Results on Mar 10, 2022

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.12 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS US$0.089 (vs US$0.20 loss in 2Q 2020)

Iridex Corporation Revises Earnings Guidance for the Year 2021

No longer forecast to breakeven

Price target increased to US$10.50

IRIDEX Corporation Provides Earnings Guidance for the Fiscal Year 2021

Iridex Corporation Announces It Cannot Provide Meaningful Financial Guidance for 2021

IRIDEX Corporation announced that it has received $10 million in funding from Topcon America Corporation

IRIDEX Corporation to Report Q4, 2020 Results on Mar 22, 2021